RIGEL PHARMACEUTICALS, INC. Debt Securities, Available-for-sale, Allowance for Credit Loss, Current
RIGEL PHARMACEUTICALS, INC. (RIGL) had Debt Securities, Available-for-sale, Allowance for Credit Loss, Current of $0 as of 2025-12-31, per its 10-K filed 2026-03-03.
Financial Statements › Notes › Credit Loss, Additional Improvements
us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossCurrent · last filed 2026-03-03
- 2025-12-31: Debt Securities, Available-for-sale, Allowance for Credit Loss, Current $0.00.
- 2024-12-31: Debt Securities, Available-for-sale, Allowance for Credit Loss, Current $0.00.
- 2023-12-31: Debt Securities, Available-for-sale, Allowance for Credit Loss, Current $0.00.
| Period end | Debt Securities, Available-for-sale, Allowance for Credit Loss, Current |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-03 |
| 2024-12-31 | $0.00 10-K · filed 2026-03-03 |
| 2023-12-31 | $0.00 10-K · filed 2025-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |